CIBC Asset Management Inc Buys 3,152 Shares of Agilent Technologies, Inc. (NYSE:A)

CIBC Asset Management Inc raised its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 7.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 43,158 shares of the medical research company’s stock after purchasing an additional 3,152 shares during the period. CIBC Asset Management Inc’s holdings in Agilent Technologies were worth $6,408,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Western Pacific Wealth Management LP raised its position in Agilent Technologies by 18.9% during the 1st quarter. Western Pacific Wealth Management LP now owns 440 shares of the medical research company’s stock worth $64,000 after purchasing an additional 70 shares during the last quarter. Menard Financial Group LLC raised its position in shares of Agilent Technologies by 1.6% in the 2nd quarter. Menard Financial Group LLC now owns 4,845 shares of the medical research company’s stock worth $628,000 after acquiring an additional 77 shares in the last quarter. McAdam LLC raised its position in shares of Agilent Technologies by 3.1% in the 3rd quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock worth $376,000 after acquiring an additional 77 shares in the last quarter. Global Retirement Partners LLC raised its position in shares of Agilent Technologies by 3.2% in the 3rd quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock worth $382,000 after acquiring an additional 79 shares in the last quarter. Finally, Rovin Capital UT ADV raised its position in shares of Agilent Technologies by 1.6% in the 3rd quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock worth $750,000 after acquiring an additional 81 shares in the last quarter.

Agilent Technologies Price Performance

A stock opened at $127.07 on Monday. The company has a market capitalization of $36.51 billion, a P/E ratio of 26.36, a price-to-earnings-growth ratio of 5.59 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. Agilent Technologies, Inc. has a 52-week low of $112.06 and a 52-week high of $155.35. The business has a 50-day simple moving average of $138.73 and a two-hundred day simple moving average of $138.00.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the previous year, the business earned $1.43 EPS. The company’s revenue was down 5.6% compared to the same quarter last year. Research analysts expect that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st were paid a $0.236 dividend. The ex-dividend date was Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.74%. Agilent Technologies’s payout ratio is presently 19.50%.

Insider Transactions at Agilent Technologies

In related news, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now owns 40,011 shares of the company’s stock, valued at approximately $5,801,595. The trade was a 19.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the sale, the chief executive officer now directly owns 24,118 shares in the company, valued at $3,497,110. This trade represents a 7.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,995 shares of company stock worth $1,739,510 in the last 90 days.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on A. UBS Group lifted their price objective on Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Barclays lifted their price objective on Agilent Technologies from $135.00 to $145.00 and gave the stock an “underweight” rating in a research report on Tuesday, October 15th. TD Cowen raised their target price on Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Bank of America raised their target price on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. Finally, Citigroup raised their target price on Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Agilent Technologies presently has an average rating of “Moderate Buy” and an average target price of $144.36.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.